NO. 5076 P. 3

JUL 1 0 2006

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Examiner:

Owens, Amelia A

Frick, et al

Art Unit:

1625

Application No.: 10/735,179

Filed:

December 12, 2003

TELEFAX CERTIFICATE

Title:

Novel Aromatic Fluoroglycoside

.

I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, Alexandria, VA 22313, on

Derivatives, Medicaments Containing These Compounds, and The use Thereof July 10, 2006

Signature

## RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

This paper is responsive to the Restriction Requirement mailed on 05/10/06. Applicant expressly reserves the right to traverse the Restriction upon further communication from the USPTO regarding the final number and characterization of Groups that the Examiner believes are patentably distinct.

Per Examiner's request, Applicant herein elects to prosecute the claims of Group I drawn to compounds. Furthermore, Applicant elects the species that is Example 1 having the following structure:

Example 1 is a compound of Formula I (Claim 1) wherein

R1 is H;

R2 is F;

R3 is OH;

A is O;

R4, R5, R6 are each H;

B is CH2 i.e. "(C1)alkanediyl";

Cycl is phenyl i.e. "a 6-membered unsaturated ring";

n is 3;

R7 is H;

R8 is OCH3 i.e. (C1)alkoxy; and

R9 is H.

Applicants submit that once the compounds of the present invention are found to be novel, then the other Groups defined by the Examiner that contain any compositions of matter containing those compounds should also be found to be novel and rejoined. Likewise, pursuant to linking claim practice, at least one of the method claims should be rejoined.

Furthermore, Applicants affirm their right to file one or more divisional applications with respect to any of the non-elected subject matter.

Respectfully submitted,

Barbara E. Kurys, Reg. No.: 34,650 Attorney/Agent for Applicant

Sanofi-Aventis Inc. LLC U.S. Patent Operations Route #202-206 / P.O. Box 6800 Bridgewater, NJ 08807-0800 Telephone (908) 231-2965 Telefax (908) 231-2626

Sanofi-Aventis Docket No. DEAV2002/0086 US NP